LONDON – Apogenix GmbH announced better-than-expected results from the final analysis of its Phase II controlled study of APG101 in the second-line treatment of glioblastoma multiforme, reporting median progression-free survival of 19.7 weeks in the treated group compared to 10.8 weeks in the control arm. Read More

LONDON – The discovery that some types of healthy brain cells release substances that can kill brain tumor cells by inducing the tumor cells to undergo cell death could point the way toward new therapies for brain tumors. Read More

LONDON – FKD Therapies Oy has secured the support of the leading urologic oncologists in the U.S. for the Phase II trial of Instiladrin, a gene therapy treatment for bladder cancer. Read More

Alkermes plc posted its most impressive quarter so far since last fall's acquisition of Elan Corp. plc's drug delivery unit and relocation of its headquarters to Dublin, Ireland, reporting total revenues of $152.2 million, a 146 percent jump over the same three-month period in 2011. Read More

If the FDA follows through on an advisory committee's recommendations, patients may finally have drug options to fight two conditions that can lead to permanent loss of vision. Read More

• Antisense Pharma GmbH, of Regensburg, Germany said it has been granted orphan drug designation from the FDA for its oncology antisense compound trabedersen to treat malignant melanoma. Previously, trabedersen has received orphan drug designation by the European EMA and the FDA in high-grade glioma (malignant brain tumor) and in advanced pancreatic cancer. Read More